The estimated Net Worth of Robert E Landry is at least $37.2 Milión dollars as of 2 February 2024. Mr. Landry owns over 400 units of Regeneron Pharmaceuticals stock worth over $27,365,122 and over the last 11 years he sold REGN stock worth over $1,909,290. In addition, he makes $7,931,540 as Chief Financial Officer a Executive Vice President - Finance at Regeneron Pharmaceuticals.
Robert has made over 49 trades of the Regeneron Pharmaceuticals stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 400 units of REGN stock worth $151,592 on 2 February 2024.
The largest trade he's ever made was exercising 16,500 units of Regeneron Pharmaceuticals stock on 16 April 2020 worth over $4,499,550. On average, Robert trades about 2,979 units every 53 days since 2013. As of 2 February 2024 he still owns at least 23,974 units of Regeneron Pharmaceuticals stock.
You can see the complete history of Mr. Landry stock trades at the bottom of the page.
Robert E. Landry serves as Chief Financial Officer, Executive Vice President - Finance of the Company. From September 2013 to December 2018, he served as Senior Vice President, Finance. Previously, Mr. Landry served as Senior Vice President, Treasurer, at Pfizer Inc. from October 2012 to August 2013 and Senior Vice President—Finance, Pfizer’s Diversified Business, from October 2009 to October 2012. Prior to those roles, Mr. Landry held a number of positions at Wyeth, which was acquired by Pfizer Inc. in October 2009, including Treasurer and Principal Corporate Officer from 2007 to 2009, Director of Pharmaceutical Marketing and Sales of Wyeth’s Australian affiliate from 2006 to 2007, and Chief Financial Officer of Wyeth’s Australian and New Zealand affiliates from 2004 to 2006.
As the Chief Financial Officer a Executive Vice President - Finance of Regeneron Pharmaceuticals, the total compensation of Robert Landry at Regeneron Pharmaceuticals is $7,931,540. There are 6 executives at Regeneron Pharmaceuticals getting paid more, with P. Roy Vagelos having the highest compensation of $22,304,300.
Robert Landry is 56, he's been the Chief Financial Officer a Executive Vice President - Finance of Regeneron Pharmaceuticals since 2019. There are 20 older and 4 younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 90, who is the Chairman of the Board, Director.
Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis a Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include: